Navigation Links
Shire Supports Rare Disease Day 2010
Date:3/1/2010

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and understanding of rare diseases.

Rare Disease Day seeks to call attention to rare diseases as a public health issue, and to reinforce the increased need for access to information, research and treatment. It is coordinated at the international level by European Organisation for Rare Diseases (EURORDIS) and by the National Organization for Rare Disorders (NORD) in the US.

It is estimated that there are between 5,000 and 8,000 known rare diseases affecting 250 million people in the world. Shire has commercially approved and available treatments for Fabry disease, Hereditary Angioedema (HAE) and Hunter syndrome. In addition, Shire expects the U.S. Food & Drug Administration (FDA) to issue its decision for VPRIVTM (velaglucerase alfa for injection), Shire's investigational enzyme replacement treatment for Type 1 Gaucher disease, by February 28.

"For many patients and their families, the journey to a diagnosis and subsequent treatment can be a long, complicated process," said Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is committed to enabling people with life-altering conditions to lead better lives - and for us, this includes improving access to information as well as providing much-needed treatment for rare diseases."

    Shire's Global Rare Disease Day Initiatives include:

    - Extending BraveCommunity.com (http://www.bravecommunity.com), its
    online resource center that aims to connect patients with each other and
    to provide important information about rare diseases.

    - Supporting the Global Genes Project (http://www.globalgenesproject.org)
    , a grassroots effort to use denim jeans to raise global awareness of
    rare genetic disorders.

    - Supporting its non-profit partners as they visit Capitol Hill to
    advocate for patients with rare diseases in Washington, D.C.,

    - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the
    Annual Running Race for Rare Disease Day in Madrid, Spain.

    - Organizing a special walk on February 28th in Brazil to raise awareness
    of rare diseases in the country. It is expected that more than 20 patient
    organizations and their members will participate.


    For the full press release please visit http://www.bravecommunity.com
    Media Contact
    Jessica Mann (Rest of the World) +44(0)1256-894-280

    Jessica Cotrone (North America, HGT) +1-617-613-4640
    http://www.shire.com

SOURCE Shire Pharmaceutical

Back to top
'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):